ScreenerHero
ORYOryzon Genomics S.A.
BME · ES · Healthcare · Biotechnology · oryzon.com
2.842EUR+2.01%Mkt Cap: 253.18M $P/E: —

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap253.18M $
Enterprise Value230.68M $
Revenue (TTM)16.75M $
Gross Profit11.58M $
Net Income (TTM)-2.83M $
Revenue/Share0.2163 USD
Last Price2.842 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryES
SectorHealthcare
IndustryBiotechnology
ISINES0167733015
Valuation
P/E (Trailing)—
P/E (Forward)309.78
PEG—
EV/EBITDA-36.33
EV/Revenue13.77
P/S14.83
P/B1.81
EPS (TTM)-0.03
EPS (Forward)0.01
52W Range
2.60017% of range4.020
52W High4.020 EUR
52W Low2.600 EUR
Profitability
Gross Margin97.75%
Oper. Margin30.77%
EBITDA Margin-37.91%
Profit Margin-15.76%
ROE-2.21%
ROA-1.80%
Growth
Revenue Growth106.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.56M $
CapEx (TTM)12.00M $
FCF Margin-106.21%
FCF Yield-7.03%
Net Debt-4.23M $
Net Debt/EBITDA0.67
Balance Sheet
Debt/Equity0.06
Current Ratio1.60
Quick Ratio1.59
Book Value/Sh1.544 EUR
Cash/Share0.1890 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.133 EUR
Upside (mean)+151.0%
Target Range4.200 EUR – 12.00 EUR
€4.200+151.0% to mean€12.00
# Analysts3
Ownership
Shares Out.81.96M
Float61.45M
Insiders20.15%
Institutions0.94%
Technical
SMA 502.978 (-4.6%)
SMA 2003.010 (-5.6%)
Beta0.44
S&P 52W Chg18.16%
Avg Vol (30d)221.77K
Avg Vol (10d)159.99K
Technical Indicators
RSI (14)30.1
MACD-0.0322
MACD Signal-0.0228
MACD Hist.-0.0094
BB Upper3.001 EUR
BB Middle2.906 EUR
BB Lower2.811 EUR
BB Width6.53%
ATR (14)0.0626 EUR
Vol Ratio (20d)1.20x